Amendment and Mail Process Complete

CELLCARTA

Caprion Biosciences, Inc.

Amendment and Mail Process Complete

Trademark Snap Shot Amendment & Mail Processing Stylesheet
(Table presents the data on Amendment & Mail Processing Complete)

OVERVIEW

SERIAL NUMBER 90112472 FILING DATE 08/13/2020
REG NUMBER 0000000 REG DATE N/A
REGISTER PRINCIPAL MARK TYPE TRADEMARK
INTL REG # N/A INTL REG DATE N/A
TM ATTORNEY LEE, OLIVIA SUNMIN
L.O. ASSIGNED O10-NOT FOUND

PUB INFORMATION

RUN DATE 12/12/2020
PUB DATE N/A
STATUS 647-EXAMINERS AMENDMENT - MAILED
STATUS DATE 12/11/2020
LITERAL MARK ELEMENT CELLCARTA

DATE ABANDONED N/A DATE CANCELLED N/A
SECTION 2F NO SECTION 2F IN PART NO
SECTION 8 NO SECTION 8 IN PART NO
SECTION 15 NO REPUB 12C N/A
RENEWAL FILED NO RENEWAL DATE N/A
DATE AMEND REG N/A


FILING BASIS

FILED BASIS CURRENT BASIS AMENDED BASIS
1 (a) NO 1 (a) NO 1 (a) NO
1 (b) YES 1 (b) YES 1 (b) NO
44D NO 44D NO 44D NO
44E NO 44E NO 44E NO
66A NO 66A NO

NO BASIS NO NO BASIS NO


MARK DATA

STANDARD CHARACTER MARK YES
LITERAL MARK ELEMENT CELLCARTA
MARK DRAWING CODE 4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG NO

CURRENT OWNER INFORMATION

PARTY TYPE 10-ORIGINAL APPLICANT
NAME Caprion Biosciences, Inc.
ADDRESS 201 President-Kennedy Ave., Suite 3900
Montreal, Quebec, H2X3Y7
ENTITY 03-CORPORATION
CITIZENSHIP Canada

GOODS AND SERVICES

INTERNATIONAL CLASS 001
          DESCRIPTION TEXT Assays for scientific and research purposes; assays for biomarker verification, validation, and application; assays for use in connection with mass spectrometry
INTERNATIONAL CLASS 009
          DESCRIPTION TEXT Downloadable or recorded software for informatics, bioinformatics; Downloadable or recorded software for clinical trial data acquisition, validation, and analysis; Downloadable or recorded software for cellular analysis, cell sorting, pathway phenotyping, and molecular surface profiling; Downloadable or recorded software for managing information related to clinical trials
INTERNATIONAL CLASS 042
          DESCRIPTION TEXT Scientific research and development; Medical research and development; Product research and development; Biochemical research and development; Pharmaceutical research and development services; Biomedical research and development services; Design and development of biochemical, pharmaceutical, and medical assays; Scientific and pharmaceutical research in the field of biomarker discovery; Scientific research and development in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, pathology, histopathology; immune monitoring, and genetic profiling for research and development purposes; scientific research and development in the field of mass cytometry, cellular analysis, cell sorting, pathway phenotyping, and molecular surface profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; providing laboratory testing services in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, pathology, histopathology; Conducting clinical trials for others; Conducting clinical trials for others in the fields of pharmaceutical, medical, and scientific research; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Conducting research and clinical trials for others in the fields of oncology, infectious diseases, autoimmune disorders, and allergies; Consulting services in the field of clinical trial research; Providing medical and scientific research information in the field of clinical trials; Research and development in the pharmaceutical and biotechnology fields; Laboratory research services relating to pharmaceuticals; Software as a service (SAAS) services featuring software for informatics, bioinformatics; software as a service (SAAS) services featuring software for clinical trial data acquisition, validation, and analysis; Software as a service (SAAS) services featuring software for cellular analysis, cell sorting, pathway phenotyping, and molecular surface profiling; Software as a service (SAAS) services featuring software for cell cytometry; Software as a service (SAAS) services featuring software for managing information related to clinical trials
INTERNATIONAL CLASS 044
          DESCRIPTION TEXT Genetic testing for medical purposes; Consulting services in the fields of diagnostic medical testing; Medical testing for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; providing medical information and advice in the fields of pathology, pharmacology, and immunology; collection, organization, analysis, and reporting of medical data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; immune monitoring, and genetic profiling for medical and diagnostic purposes
INTERNATIONAL CLASS 045
          DESCRIPTION TEXT Regulatory compliance consulting in the fields of pharmaceuticals and clinical diagnostics; Advice and consultancy on food, drug, and medical device regulatory matters; regulatory compliance consulting in the field of obtaining government authorization to market pharmaceuticals and medical device

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS 001 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 009 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 042 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 044 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE
INTERNATIONAL CLASS 045 FIRST USE DATE NONE FIRST USE IN COMMERCE DATE NONE CLASS STATUS 6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION NO

PROSECUTION HISTORY

DATE ENT CD ENT TYPE DESCRIPTION ENT NUM
12/11/2020 XAEC I EXAMINER'S AMENDMENT ENTERED 010
12/11/2020 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED 009
12/11/2020 GNEA O EXAMINERS AMENDMENT E-MAILED 008
12/11/2020 CNEA R EXAMINERS AMENDMENT -WRITTEN 007
12/09/2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED 006
12/09/2020 GNRT F NON-FINAL ACTION E-MAILED 005
12/09/2020 CNRT R NON-FINAL ACTION WRITTEN 004
12/08/2020 DOCK D ASSIGNED TO EXAMINER 003
09/17/2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM 002
08/17/2020 NWAP I NEW APPLICATION ENTERED IN TRAM 001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY Keith Toms, Esq.
CORRESPONDENCE ADDRESS KEITH TOMS, ESQ.
MCCARTER & ENGLISH, LLP
265 FRANKLIN STREET
BOSTON, MA 02110-3113
DOMESTIC REPRESENTATIVE NONE

Amendment and Mail Process Complete [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed